Vinay Prasad, M.D., has rejoined the FDA, the latest turn in a monthslong stretch of leadership turnover at the agency. | “At ...

The Food and Drug Administration's polarizing vaccine chief is leaving the agency after a brief tenure that drew the ire of biotech executives, patient groups and conservative allies of President ...

Vinay Prasad is returning to his role overseeing vaccine, gene therapy and blood product regulation at the U.S. Food and Drug ...

Dr Vinay Prasad will return to head the FDA’s Center for Biologics Evaluation and Research less than 2 weeks after being ousted.

Vinay Prasad returns as FDA's CBER director after brief exit, raising questions on rare disease drug approvals and mRNA ...

DIRECTING A CHANGING CDC — The Senate voted to confirm Susan Monarez as the next CDC director Tuesday, marking an end to the ...

Vinay Prasad was reinstated as the head of the Center for Biologics Evaluation and Research (CBER) at the US Food and Drug Administration (FDA) on 11 August. He had resigned on 29 July.1 “At the FDA’s ...

Dr. Vinay Prasad had been serving as the FDA's director of the Center for Biologics Evaluation and Research since May, and was later named chief medical and scientific officer.

Vinay Prasad, a top vaccine regulator ousted from the Food and Drug Administration (FDA) late last month, is set to return to his post, according to the Department of Health and Human Services ...

He is also known for examining financial conflicts in drug approvals. FDA appointment and departure in 2025 Prasad was appointed Director of the FDA's CBER on May 6, 2025.